These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 76325)

  • 1. [Value of testosterone, FSH and LH on plasma in patients with prostatic adenoma and carcinoma before and after different hormonal treatments].
    Garcia de la Peña E; Ramos F; Horcajada C; Cifuentes Delatte L; Vivanco F
    Rev Clin Esp; 1978 Jan; 148(1):19-23. PubMed ID: 76325
    [No Abstract]   [Full Text] [Related]  

  • 2. [Effect of hormonal therapy on plasma FSH, LH and testosterone levels in prostatic cancer].
    Shirai M; Matsuda S; Mitsukawa S; Nakamura M; Yonezawa K
    Nihon Hinyokika Gakkai Zasshi; 1975 Feb; 66(2):59-67. PubMed ID: 1168823
    [No Abstract]   [Full Text] [Related]  

  • 3. Hormonal status in prostatic disease.
    Frick J; Bartsch G
    Prog Clin Biol Res; 1976; 6():143-58. PubMed ID: 66687
    [No Abstract]   [Full Text] [Related]  

  • 4. [Pre- and post-prostatectomy variation and supplement of sexual hormones in patients with benign prostatic hyperplasia].
    Ren XM; Ying J; Yao DH; Jiang YQ; Xu MX
    Zhonghua Nan Ke Xue; 2005 Jan; 11(1):50-2, 55. PubMed ID: 15704683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hormonal environment and antiandrogenic treatment in benign prostatic hypertrophy].
    Katayama T; Umeda K; Kazama T
    Hinyokika Kiyo; 1986 Nov; 32(11):1584-9. PubMed ID: 2435122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Determination of LH and FSH levels before and after prostatic adenomectomy (author's transl)].
    Fontana D; Isaia GC; Fasolis G; Bertagna A; Borgno M; Molinatti GM
    J Urol Nephrol (Paris); 1979; 85(7-8):479-84. PubMed ID: 93649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hormonal disturbances in men with a prostatic adenoma (author's transl)].
    Baranowska B; Zgliczynski S; Szymanowski J
    J Urol (Paris); 1980; 86(7):551-8. PubMed ID: 6161196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Plasma testosterone: a sound criterion of the effectiveness of hormonal treatment of prostatic carcinoma].
    Maleeva A; Tsvetkov M; Kekhaĭova M
    Vutr Boles; 1980; 19(3):42-6. PubMed ID: 6771918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment with D-Trp-6-LHRH. Plasma levels and gonadotropic response].
    Lahlou N; Duchier J; Feinstein MC; Mauvernay RY; Roger M; Schally AV
    Pathol Biol (Paris); 1984 Oct; 32(8):906-8. PubMed ID: 6209605
    [No Abstract]   [Full Text] [Related]  

  • 10. Hormonal predictors of prostate cancer.
    Sofikerim M; Eskicorapci S; Oruç O; Ozen H
    Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Study of the interdependence between prostatic hypertrophy and disorders in hormone levels. Preliminary report. 1. Study of blood testosterone].
    Szymanoski J; Baranowska B; Migdalska B; Kozlowicz I
    J Urol Nephrol (Paris); 1976; 82(10-11):827-36. PubMed ID: 63569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Behavior of LH, FSH, total testosterone, free testosterone and SHBG serum levels in the therapy of prostatic cancer with Turisteron (ethinyl estradiol sulfonate)].
    Guddat HM; Schnorr D; Dörner G; Stahl F; Rohde W
    Z Urol Nephrol; 1987 Dec; 80(12):665-8. PubMed ID: 3126615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hormonal changes in carcinoma of the prostate].
    Rodrigues-Netto Júnior N; Da Silva RP; Hernández AJ
    Rev Paul Med; 1979; 94(1-2):24-6. PubMed ID: 120973
    [No Abstract]   [Full Text] [Related]  

  • 14. [The influence of spironolactone on the concentration of gonadotrophins and gonadal hormones in prostatic hypertrophy (author's transl)].
    Zgliczynski S; Baranowska B; Szymanowski J
    J Urol (Paris); 1981; 87(9):635-8. PubMed ID: 6174646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Some effects of orchiectomy, oestrogen treatment and radiation therapy in patients with prostatic carcinoma.
    Tomić R
    Scand J Urol Nephrol Suppl; 1983; 77():1-37. PubMed ID: 6426040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A study of the endocrine manifestations of hepatic cirrhosis.
    Baker HW; Burger HG; de Kretser DM; Dulmanis A; Hudson B; O'Connor S; Paulsen CA; Purcell N; Rennie GC; Seah CS; Taft HP; Wang C
    Q J Med; 1976 Jan; 45(177):145-78. PubMed ID: 769039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testosterone levels in benign prostatic hypertrophy and prostate cancer.
    Mearini L; Costantini E; Zucchi A; Mearini E; Bini V; Cottini E; Porena M
    Urol Int; 2008; 80(2):134-40. PubMed ID: 18362481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum levels of follicle stimulating hormone, luteinizing hormone, prolactin, testosterone, 5 alpha-dihydrotestosterone, 5 alpha-androstane-3 alpha, 17 beta-diol, 5 alpha-androstane-3 beta, 17 beta-diol, and 17 beta-estradiol from male beagles with spontaneous or induced benign prostatic hyperplasia.
    Cochran RC; Ewing LL; Niswender GD
    Invest Urol; 1981 Nov; 19(3):142-7. PubMed ID: 6170603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of long term treatment with finasteride (MK-906), a 5-alpha reductase inhibitor, on circulating LH, FSH, prolactin and estradiol.
    Matzkin H; Chen J; Lewyshon O; Ayalon D; Braf Z
    Horm Metab Res; 1992 Oct; 24(10):498-9. PubMed ID: 1281461
    [No Abstract]   [Full Text] [Related]  

  • 20. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
    Kobayashi T; Nishizawa K; Mitsumori K
    Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.